Global Moderate to Severe Plaque Psoriasis Medications Market Growth 2026-2032
The global Moderate to Severe Plaque Psoriasis Medications market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
The driving factors for moderate to severe plaque psoriasis drugs mainly include the following aspects:
Disease severity: Patients with moderate to severe plaque psoriasis have a more severe condition and require medication to control the progression of the disease and relieve symptoms. Therefore, there is a high demand for drugs for moderate to severe plaque psoriasis, which promotes the development and application of related drugs.
Medical needs: Psoriasis is a chronic, relapsing, inflammatory skin disease that requires long-term treatment and management. Therefore, the increase in medical demand has also promoted the development and application of drugs for moderate to severe plaque psoriasis.
Development of science and technology: With the continuous advancement of science and technology, new drugs and technical means are constantly emerging, providing more possibilities and opportunities for the development and application of drugs for moderate to severe plaque psoriasis. For example, new drug formulations, delivery methods, treatment methods, etc. can improve treatment effects and patient compliance.
Policy support: The government and regulatory agencies provide policy support for the research, development and application of innovative drugs and encourage pharmaceutical companies to conduct research and development. This also provides more opportunities and resources for the research, development and application of drugs for moderate to severe plaque psoriasis. .
Market demand: As the number of psoriasis patients continues to increase, the market demand is also growing. The demand from patients and doctors for drugs with better therapeutic effects has also driven the development and application of drugs for moderate to severe plaque psoriasis.
LP Information, Inc. (LPI) ' newest research report, the “Moderate to Severe Plaque Psoriasis Medications Industry Forecast” looks at past sales and reviews total world Moderate to Severe Plaque Psoriasis Medications sales in 2025, providing a comprehensive analysis by region and market sector of projected Moderate to Severe Plaque Psoriasis Medications sales for 2026 through 2032. With Moderate to Severe Plaque Psoriasis Medications sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Moderate to Severe Plaque Psoriasis Medications industry.
This Insight Report provides a comprehensive analysis of the global Moderate to Severe Plaque Psoriasis Medications landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Moderate to Severe Plaque Psoriasis Medications portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Moderate to Severe Plaque Psoriasis Medications market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Moderate to Severe Plaque Psoriasis Medications and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Moderate to Severe Plaque Psoriasis Medications.
This report presents a comprehensive overview, market shares, and growth opportunities of Moderate to Severe Plaque Psoriasis Medications market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
The driving factors for moderate to severe plaque psoriasis drugs mainly include the following aspects:
Disease severity: Patients with moderate to severe plaque psoriasis have a more severe condition and require medication to control the progression of the disease and relieve symptoms. Therefore, there is a high demand for drugs for moderate to severe plaque psoriasis, which promotes the development and application of related drugs.
Medical needs: Psoriasis is a chronic, relapsing, inflammatory skin disease that requires long-term treatment and management. Therefore, the increase in medical demand has also promoted the development and application of drugs for moderate to severe plaque psoriasis.
Development of science and technology: With the continuous advancement of science and technology, new drugs and technical means are constantly emerging, providing more possibilities and opportunities for the development and application of drugs for moderate to severe plaque psoriasis. For example, new drug formulations, delivery methods, treatment methods, etc. can improve treatment effects and patient compliance.
Policy support: The government and regulatory agencies provide policy support for the research, development and application of innovative drugs and encourage pharmaceutical companies to conduct research and development. This also provides more opportunities and resources for the research, development and application of drugs for moderate to severe plaque psoriasis. .
Market demand: As the number of psoriasis patients continues to increase, the market demand is also growing. The demand from patients and doctors for drugs with better therapeutic effects has also driven the development and application of drugs for moderate to severe plaque psoriasis.
LP Information, Inc. (LPI) ' newest research report, the “Moderate to Severe Plaque Psoriasis Medications Industry Forecast” looks at past sales and reviews total world Moderate to Severe Plaque Psoriasis Medications sales in 2025, providing a comprehensive analysis by region and market sector of projected Moderate to Severe Plaque Psoriasis Medications sales for 2026 through 2032. With Moderate to Severe Plaque Psoriasis Medications sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Moderate to Severe Plaque Psoriasis Medications industry.
This Insight Report provides a comprehensive analysis of the global Moderate to Severe Plaque Psoriasis Medications landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Moderate to Severe Plaque Psoriasis Medications portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Moderate to Severe Plaque Psoriasis Medications market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Moderate to Severe Plaque Psoriasis Medications and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Moderate to Severe Plaque Psoriasis Medications.
This report presents a comprehensive overview, market shares, and growth opportunities of Moderate to Severe Plaque Psoriasis Medications market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Injection
- Oral
- Topical Cream
- Hospital Clinic
- Pharmacy
- Online Shopping Mall
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Janssen Biotech
- Abbvie
- Sandoz
- Amgen
- Eli Lilly
- Novartis
- Sun Pharmaceutical Industries
- UCB, Inc
- Dermavant Sciences
- GSK
- What is the 10-year outlook for the global Moderate to Severe Plaque Psoriasis Medications market?
- What factors are driving Moderate to Severe Plaque Psoriasis Medications market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Moderate to Severe Plaque Psoriasis Medications market opportunities vary by end market size?
- How does Moderate to Severe Plaque Psoriasis Medications break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Moderate to Severe Plaque Psoriasis Medications Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Moderate to Severe Plaque Psoriasis Medications by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Moderate to Severe Plaque Psoriasis Medications by Country/Region, 2021, 2025 & 2032
2.2 Moderate to Severe Plaque Psoriasis Medications Segment by Type
2.2.1 Injection
2.2.2 Oral
2.2.3 Topical Cream
2.2.4 Moderate to Severe Plaque Psoriasis Medications Sales by Type
2.2.4.1 Global Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Type (2021-2026)
2.2.4.2 Global Moderate to Severe Plaque Psoriasis Medications Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Moderate to Severe Plaque Psoriasis Medications Sale Price by Type (2021-2026)
2.3 Moderate to Severe Plaque Psoriasis Medications Segment by Application
2.3.1 Hospital Clinic
2.3.2 Pharmacy
2.3.3 Online Shopping Mall
2.3.4 Moderate to Severe Plaque Psoriasis Medications Sales by Application
2.3.4.1 Global Moderate to Severe Plaque Psoriasis Medications Sale Market Share by Application (2021-2026)
2.3.4.2 Global Moderate to Severe Plaque Psoriasis Medications Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Moderate to Severe Plaque Psoriasis Medications Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Moderate to Severe Plaque Psoriasis Medications Breakdown Data by Company
3.1.1 Global Moderate to Severe Plaque Psoriasis Medications Annual Sales by Company (2021-2026)
3.1.2 Global Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Company (2021-2026)
3.2 Global Moderate to Severe Plaque Psoriasis Medications Annual Revenue by Company (2021-2026)
3.2.1 Global Moderate to Severe Plaque Psoriasis Medications Revenue by Company (2021-2026)
3.2.2 Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Company (2021-2026)
3.3 Global Moderate to Severe Plaque Psoriasis Medications Sale Price by Company
3.4 Key Manufacturers Moderate to Severe Plaque Psoriasis Medications Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Moderate to Severe Plaque Psoriasis Medications Product Location Distribution
3.4.2 Players Moderate to Severe Plaque Psoriasis Medications Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR MODERATE TO SEVERE PLAQUE PSORIASIS MEDICATIONS BY GEOGRAPHIC REGION
4.1 World Historic Moderate to Severe Plaque Psoriasis Medications Market Size by Geographic Region (2021-2026)
4.1.1 Global Moderate to Severe Plaque Psoriasis Medications Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Moderate to Severe Plaque Psoriasis Medications Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Moderate to Severe Plaque Psoriasis Medications Market Size by Country/Region (2021-2026)
4.2.1 Global Moderate to Severe Plaque Psoriasis Medications Annual Sales by Country/Region (2021-2026)
4.2.2 Global Moderate to Severe Plaque Psoriasis Medications Annual Revenue by Country/Region (2021-2026)
4.3 Americas Moderate to Severe Plaque Psoriasis Medications Sales Growth
4.4 APAC Moderate to Severe Plaque Psoriasis Medications Sales Growth
4.5 Europe Moderate to Severe Plaque Psoriasis Medications Sales Growth
4.6 Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Sales Growth
5 AMERICAS
5.1 Americas Moderate to Severe Plaque Psoriasis Medications Sales by Country
5.1.1 Americas Moderate to Severe Plaque Psoriasis Medications Sales by Country (2021-2026)
5.1.2 Americas Moderate to Severe Plaque Psoriasis Medications Revenue by Country (2021-2026)
5.2 Americas Moderate to Severe Plaque Psoriasis Medications Sales by Type (2021-2026)
5.3 Americas Moderate to Severe Plaque Psoriasis Medications Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Moderate to Severe Plaque Psoriasis Medications Sales by Region
6.1.1 APAC Moderate to Severe Plaque Psoriasis Medications Sales by Region (2021-2026)
6.1.2 APAC Moderate to Severe Plaque Psoriasis Medications Revenue by Region (2021-2026)
6.2 APAC Moderate to Severe Plaque Psoriasis Medications Sales by Type (2021-2026)
6.3 APAC Moderate to Severe Plaque Psoriasis Medications Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Moderate to Severe Plaque Psoriasis Medications by Country
7.1.1 Europe Moderate to Severe Plaque Psoriasis Medications Sales by Country (2021-2026)
7.1.2 Europe Moderate to Severe Plaque Psoriasis Medications Revenue by Country (2021-2026)
7.2 Europe Moderate to Severe Plaque Psoriasis Medications Sales by Type (2021-2026)
7.3 Europe Moderate to Severe Plaque Psoriasis Medications Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Moderate to Severe Plaque Psoriasis Medications by Country
8.1.1 Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Sales by Country (2021-2026)
8.1.2 Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Revenue by Country (2021-2026)
8.2 Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Sales by Type (2021-2026)
8.3 Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Moderate to Severe Plaque Psoriasis Medications
10.3 Manufacturing Process Analysis of Moderate to Severe Plaque Psoriasis Medications
10.4 Industry Chain Structure of Moderate to Severe Plaque Psoriasis Medications
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Moderate to Severe Plaque Psoriasis Medications Distributors
11.3 Moderate to Severe Plaque Psoriasis Medications Customer
12 WORLD FORECAST REVIEW FOR MODERATE TO SEVERE PLAQUE PSORIASIS MEDICATIONS BY GEOGRAPHIC REGION
12.1 Global Moderate to Severe Plaque Psoriasis Medications Market Size Forecast by Region
12.1.1 Global Moderate to Severe Plaque Psoriasis Medications Forecast by Region (2027-2032)
12.1.2 Global Moderate to Severe Plaque Psoriasis Medications Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Moderate to Severe Plaque Psoriasis Medications Forecast by Type (2027-2032)
12.7 Global Moderate to Severe Plaque Psoriasis Medications Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Janssen Biotech
13.1.1 Janssen Biotech Company Information
13.1.2 Janssen Biotech Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
13.1.3 Janssen Biotech Moderate to Severe Plaque Psoriasis Medications Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Janssen Biotech Main Business Overview
13.1.5 Janssen Biotech Latest Developments
13.2 Abbvie
13.2.1 Abbvie Company Information
13.2.2 Abbvie Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
13.2.3 Abbvie Moderate to Severe Plaque Psoriasis Medications Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Abbvie Main Business Overview
13.2.5 Abbvie Latest Developments
13.3 Sandoz
13.3.1 Sandoz Company Information
13.3.2 Sandoz Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
13.3.3 Sandoz Moderate to Severe Plaque Psoriasis Medications Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Sandoz Main Business Overview
13.3.5 Sandoz Latest Developments
13.4 Amgen
13.4.1 Amgen Company Information
13.4.2 Amgen Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
13.4.3 Amgen Moderate to Severe Plaque Psoriasis Medications Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Amgen Main Business Overview
13.4.5 Amgen Latest Developments
13.5 Eli Lilly
13.5.1 Eli Lilly Company Information
13.5.2 Eli Lilly Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
13.5.3 Eli Lilly Moderate to Severe Plaque Psoriasis Medications Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Eli Lilly Main Business Overview
13.5.5 Eli Lilly Latest Developments
13.6 Novartis
13.6.1 Novartis Company Information
13.6.2 Novartis Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
13.6.3 Novartis Moderate to Severe Plaque Psoriasis Medications Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Novartis Main Business Overview
13.6.5 Novartis Latest Developments
13.7 Sun Pharmaceutical Industries
13.7.1 Sun Pharmaceutical Industries Company Information
13.7.2 Sun Pharmaceutical Industries Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
13.7.3 Sun Pharmaceutical Industries Moderate to Severe Plaque Psoriasis Medications Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Sun Pharmaceutical Industries Main Business Overview
13.7.5 Sun Pharmaceutical Industries Latest Developments
13.8 UCB, Inc
13.8.1 UCB, Inc Company Information
13.8.2 UCB, Inc Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
13.8.3 UCB, Inc Moderate to Severe Plaque Psoriasis Medications Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 UCB, Inc Main Business Overview
13.8.5 UCB, Inc Latest Developments
13.9 Dermavant Sciences
13.9.1 Dermavant Sciences Company Information
13.9.2 Dermavant Sciences Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
13.9.3 Dermavant Sciences Moderate to Severe Plaque Psoriasis Medications Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Dermavant Sciences Main Business Overview
13.9.5 Dermavant Sciences Latest Developments
13.10 GSK
13.10.1 GSK Company Information
13.10.2 GSK Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
13.10.3 GSK Moderate to Severe Plaque Psoriasis Medications Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 GSK Main Business Overview
13.10.5 GSK Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Moderate to Severe Plaque Psoriasis Medications Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Moderate to Severe Plaque Psoriasis Medications by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Moderate to Severe Plaque Psoriasis Medications by Country/Region, 2021, 2025 & 2032
2.2 Moderate to Severe Plaque Psoriasis Medications Segment by Type
2.2.1 Injection
2.2.2 Oral
2.2.3 Topical Cream
2.2.4 Moderate to Severe Plaque Psoriasis Medications Sales by Type
2.2.4.1 Global Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Type (2021-2026)
2.2.4.2 Global Moderate to Severe Plaque Psoriasis Medications Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Moderate to Severe Plaque Psoriasis Medications Sale Price by Type (2021-2026)
2.3 Moderate to Severe Plaque Psoriasis Medications Segment by Application
2.3.1 Hospital Clinic
2.3.2 Pharmacy
2.3.3 Online Shopping Mall
2.3.4 Moderate to Severe Plaque Psoriasis Medications Sales by Application
2.3.4.1 Global Moderate to Severe Plaque Psoriasis Medications Sale Market Share by Application (2021-2026)
2.3.4.2 Global Moderate to Severe Plaque Psoriasis Medications Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Moderate to Severe Plaque Psoriasis Medications Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Moderate to Severe Plaque Psoriasis Medications Breakdown Data by Company
3.1.1 Global Moderate to Severe Plaque Psoriasis Medications Annual Sales by Company (2021-2026)
3.1.2 Global Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Company (2021-2026)
3.2 Global Moderate to Severe Plaque Psoriasis Medications Annual Revenue by Company (2021-2026)
3.2.1 Global Moderate to Severe Plaque Psoriasis Medications Revenue by Company (2021-2026)
3.2.2 Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Company (2021-2026)
3.3 Global Moderate to Severe Plaque Psoriasis Medications Sale Price by Company
3.4 Key Manufacturers Moderate to Severe Plaque Psoriasis Medications Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Moderate to Severe Plaque Psoriasis Medications Product Location Distribution
3.4.2 Players Moderate to Severe Plaque Psoriasis Medications Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR MODERATE TO SEVERE PLAQUE PSORIASIS MEDICATIONS BY GEOGRAPHIC REGION
4.1 World Historic Moderate to Severe Plaque Psoriasis Medications Market Size by Geographic Region (2021-2026)
4.1.1 Global Moderate to Severe Plaque Psoriasis Medications Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Moderate to Severe Plaque Psoriasis Medications Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Moderate to Severe Plaque Psoriasis Medications Market Size by Country/Region (2021-2026)
4.2.1 Global Moderate to Severe Plaque Psoriasis Medications Annual Sales by Country/Region (2021-2026)
4.2.2 Global Moderate to Severe Plaque Psoriasis Medications Annual Revenue by Country/Region (2021-2026)
4.3 Americas Moderate to Severe Plaque Psoriasis Medications Sales Growth
4.4 APAC Moderate to Severe Plaque Psoriasis Medications Sales Growth
4.5 Europe Moderate to Severe Plaque Psoriasis Medications Sales Growth
4.6 Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Sales Growth
5 AMERICAS
5.1 Americas Moderate to Severe Plaque Psoriasis Medications Sales by Country
5.1.1 Americas Moderate to Severe Plaque Psoriasis Medications Sales by Country (2021-2026)
5.1.2 Americas Moderate to Severe Plaque Psoriasis Medications Revenue by Country (2021-2026)
5.2 Americas Moderate to Severe Plaque Psoriasis Medications Sales by Type (2021-2026)
5.3 Americas Moderate to Severe Plaque Psoriasis Medications Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Moderate to Severe Plaque Psoriasis Medications Sales by Region
6.1.1 APAC Moderate to Severe Plaque Psoriasis Medications Sales by Region (2021-2026)
6.1.2 APAC Moderate to Severe Plaque Psoriasis Medications Revenue by Region (2021-2026)
6.2 APAC Moderate to Severe Plaque Psoriasis Medications Sales by Type (2021-2026)
6.3 APAC Moderate to Severe Plaque Psoriasis Medications Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Moderate to Severe Plaque Psoriasis Medications by Country
7.1.1 Europe Moderate to Severe Plaque Psoriasis Medications Sales by Country (2021-2026)
7.1.2 Europe Moderate to Severe Plaque Psoriasis Medications Revenue by Country (2021-2026)
7.2 Europe Moderate to Severe Plaque Psoriasis Medications Sales by Type (2021-2026)
7.3 Europe Moderate to Severe Plaque Psoriasis Medications Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Moderate to Severe Plaque Psoriasis Medications by Country
8.1.1 Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Sales by Country (2021-2026)
8.1.2 Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Revenue by Country (2021-2026)
8.2 Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Sales by Type (2021-2026)
8.3 Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Moderate to Severe Plaque Psoriasis Medications
10.3 Manufacturing Process Analysis of Moderate to Severe Plaque Psoriasis Medications
10.4 Industry Chain Structure of Moderate to Severe Plaque Psoriasis Medications
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Moderate to Severe Plaque Psoriasis Medications Distributors
11.3 Moderate to Severe Plaque Psoriasis Medications Customer
12 WORLD FORECAST REVIEW FOR MODERATE TO SEVERE PLAQUE PSORIASIS MEDICATIONS BY GEOGRAPHIC REGION
12.1 Global Moderate to Severe Plaque Psoriasis Medications Market Size Forecast by Region
12.1.1 Global Moderate to Severe Plaque Psoriasis Medications Forecast by Region (2027-2032)
12.1.2 Global Moderate to Severe Plaque Psoriasis Medications Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Moderate to Severe Plaque Psoriasis Medications Forecast by Type (2027-2032)
12.7 Global Moderate to Severe Plaque Psoriasis Medications Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Janssen Biotech
13.1.1 Janssen Biotech Company Information
13.1.2 Janssen Biotech Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
13.1.3 Janssen Biotech Moderate to Severe Plaque Psoriasis Medications Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Janssen Biotech Main Business Overview
13.1.5 Janssen Biotech Latest Developments
13.2 Abbvie
13.2.1 Abbvie Company Information
13.2.2 Abbvie Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
13.2.3 Abbvie Moderate to Severe Plaque Psoriasis Medications Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Abbvie Main Business Overview
13.2.5 Abbvie Latest Developments
13.3 Sandoz
13.3.1 Sandoz Company Information
13.3.2 Sandoz Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
13.3.3 Sandoz Moderate to Severe Plaque Psoriasis Medications Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Sandoz Main Business Overview
13.3.5 Sandoz Latest Developments
13.4 Amgen
13.4.1 Amgen Company Information
13.4.2 Amgen Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
13.4.3 Amgen Moderate to Severe Plaque Psoriasis Medications Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Amgen Main Business Overview
13.4.5 Amgen Latest Developments
13.5 Eli Lilly
13.5.1 Eli Lilly Company Information
13.5.2 Eli Lilly Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
13.5.3 Eli Lilly Moderate to Severe Plaque Psoriasis Medications Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Eli Lilly Main Business Overview
13.5.5 Eli Lilly Latest Developments
13.6 Novartis
13.6.1 Novartis Company Information
13.6.2 Novartis Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
13.6.3 Novartis Moderate to Severe Plaque Psoriasis Medications Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Novartis Main Business Overview
13.6.5 Novartis Latest Developments
13.7 Sun Pharmaceutical Industries
13.7.1 Sun Pharmaceutical Industries Company Information
13.7.2 Sun Pharmaceutical Industries Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
13.7.3 Sun Pharmaceutical Industries Moderate to Severe Plaque Psoriasis Medications Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Sun Pharmaceutical Industries Main Business Overview
13.7.5 Sun Pharmaceutical Industries Latest Developments
13.8 UCB, Inc
13.8.1 UCB, Inc Company Information
13.8.2 UCB, Inc Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
13.8.3 UCB, Inc Moderate to Severe Plaque Psoriasis Medications Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 UCB, Inc Main Business Overview
13.8.5 UCB, Inc Latest Developments
13.9 Dermavant Sciences
13.9.1 Dermavant Sciences Company Information
13.9.2 Dermavant Sciences Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
13.9.3 Dermavant Sciences Moderate to Severe Plaque Psoriasis Medications Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Dermavant Sciences Main Business Overview
13.9.5 Dermavant Sciences Latest Developments
13.10 GSK
13.10.1 GSK Company Information
13.10.2 GSK Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
13.10.3 GSK Moderate to Severe Plaque Psoriasis Medications Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 GSK Main Business Overview
13.10.5 GSK Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Moderate to Severe Plaque Psoriasis Medications Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Moderate to Severe Plaque Psoriasis Medications Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Injection
Table 4. Major Players of Oral
Table 5. Major Players of Topical Cream
Table 6. Global Moderate to Severe Plaque Psoriasis Medications Sales by Type (2021-2026) & (K Units)
Table 7. Global Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Type (2021-2026)
Table 8. Global Moderate to Severe Plaque Psoriasis Medications Revenue by Type (2021-2026) & ($ million)
Table 9. Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Type (2021-2026)
Table 10. Global Moderate to Severe Plaque Psoriasis Medications Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Global Moderate to Severe Plaque Psoriasis Medications Sale by Application (2021-2026) & (K Units)
Table 12. Global Moderate to Severe Plaque Psoriasis Medications Sale Market Share by Application (2021-2026)
Table 13. Global Moderate to Severe Plaque Psoriasis Medications Revenue by Application (2021-2026) & ($ million)
Table 14. Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Application (2021-2026)
Table 15. Global Moderate to Severe Plaque Psoriasis Medications Sale Price by Application (2021-2026) & (US$/Unit)
Table 16. Global Moderate to Severe Plaque Psoriasis Medications Sales by Company (2021-2026) & (K Units)
Table 17. Global Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Company (2021-2026)
Table 18. Global Moderate to Severe Plaque Psoriasis Medications Revenue by Company (2021-2026) & ($ millions)
Table 19. Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Company (2021-2026)
Table 20. Global Moderate to Severe Plaque Psoriasis Medications Sale Price by Company (2021-2026) & (US$/Unit)
Table 21. Key Manufacturers Moderate to Severe Plaque Psoriasis Medications Producing Area Distribution and Sales Area
Table 22. Players Moderate to Severe Plaque Psoriasis Medications Products Offered
Table 23. Moderate to Severe Plaque Psoriasis Medications Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Moderate to Severe Plaque Psoriasis Medications Sales by Geographic Region (2021-2026) & (K Units)
Table 27. Global Moderate to Severe Plaque Psoriasis Medications Sales Market Share Geographic Region (2021-2026)
Table 28. Global Moderate to Severe Plaque Psoriasis Medications Revenue by Geographic Region (2021-2026) & ($ millions)
Table 29. Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Geographic Region (2021-2026)
Table 30. Global Moderate to Severe Plaque Psoriasis Medications Sales by Country/Region (2021-2026) & (K Units)
Table 31. Global Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Country/Region (2021-2026)
Table 32. Global Moderate to Severe Plaque Psoriasis Medications Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas Moderate to Severe Plaque Psoriasis Medications Sales by Country (2021-2026) & (K Units)
Table 35. Americas Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Country (2021-2026)
Table 36. Americas Moderate to Severe Plaque Psoriasis Medications Revenue by Country (2021-2026) & ($ millions)
Table 37. Americas Moderate to Severe Plaque Psoriasis Medications Sales by Type (2021-2026) & (K Units)
Table 38. Americas Moderate to Severe Plaque Psoriasis Medications Sales by Application (2021-2026) & (K Units)
Table 39. APAC Moderate to Severe Plaque Psoriasis Medications Sales by Region (2021-2026) & (K Units)
Table 40. APAC Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Region (2021-2026)
Table 41. APAC Moderate to Severe Plaque Psoriasis Medications Revenue by Region (2021-2026) & ($ millions)
Table 42. APAC Moderate to Severe Plaque Psoriasis Medications Sales by Type (2021-2026) & (K Units)
Table 43. APAC Moderate to Severe Plaque Psoriasis Medications Sales by Application (2021-2026) & (K Units)
Table 44. Europe Moderate to Severe Plaque Psoriasis Medications Sales by Country (2021-2026) & (K Units)
Table 45. Europe Moderate to Severe Plaque Psoriasis Medications Revenue by Country (2021-2026) & ($ millions)
Table 46. Europe Moderate to Severe Plaque Psoriasis Medications Sales by Type (2021-2026) & (K Units)
Table 47. Europe Moderate to Severe Plaque Psoriasis Medications Sales by Application (2021-2026) & (K Units)
Table 48. Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Sales by Country (2021-2026) & (K Units)
Table 49. Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Country (2021-2026)
Table 50. Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Sales by Type (2021-2026) & (K Units)
Table 51. Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Sales by Application (2021-2026) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Moderate to Severe Plaque Psoriasis Medications
Table 53. Key Market Challenges & Risks of Moderate to Severe Plaque Psoriasis Medications
Table 54. Key Industry Trends of Moderate to Severe Plaque Psoriasis Medications
Table 55. Moderate to Severe Plaque Psoriasis Medications Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Moderate to Severe Plaque Psoriasis Medications Distributors List
Table 58. Moderate to Severe Plaque Psoriasis Medications Customer List
Table 59. Global Moderate to Severe Plaque Psoriasis Medications Sales Forecast by Region (2027-2032) & (K Units)
Table 60. Global Moderate to Severe Plaque Psoriasis Medications Revenue Forecast by Region (2027-2032) & ($ millions)
Table 61. Americas Moderate to Severe Plaque Psoriasis Medications Sales Forecast by Country (2027-2032) & (K Units)
Table 62. Americas Moderate to Severe Plaque Psoriasis Medications Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 63. APAC Moderate to Severe Plaque Psoriasis Medications Sales Forecast by Region (2027-2032) & (K Units)
Table 64. APAC Moderate to Severe Plaque Psoriasis Medications Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Europe Moderate to Severe Plaque Psoriasis Medications Sales Forecast by Country (2027-2032) & (K Units)
Table 66. Europe Moderate to Severe Plaque Psoriasis Medications Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Global Moderate to Severe Plaque Psoriasis Medications Sales Forecast by Type (2027-2032) & (K Units)
Table 70. Global Moderate to Severe Plaque Psoriasis Medications Revenue Forecast by Type (2027-2032) & ($ millions)
Table 71. Global Moderate to Severe Plaque Psoriasis Medications Sales Forecast by Application (2027-2032) & (K Units)
Table 72. Global Moderate to Severe Plaque Psoriasis Medications Revenue Forecast by Application (2027-2032) & ($ millions)
Table 73. Janssen Biotech Basic Information, Moderate to Severe Plaque Psoriasis Medications Manufacturing Base, Sales Area and Its Competitors
Table 74. Janssen Biotech Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
Table 75. Janssen Biotech Moderate to Severe Plaque Psoriasis Medications Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Janssen Biotech Main Business
Table 77. Janssen Biotech Latest Developments
Table 78. Abbvie Basic Information, Moderate to Severe Plaque Psoriasis Medications Manufacturing Base, Sales Area and Its Competitors
Table 79. Abbvie Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
Table 80. Abbvie Moderate to Severe Plaque Psoriasis Medications Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Abbvie Main Business
Table 82. Abbvie Latest Developments
Table 83. Sandoz Basic Information, Moderate to Severe Plaque Psoriasis Medications Manufacturing Base, Sales Area and Its Competitors
Table 84. Sandoz Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
Table 85. Sandoz Moderate to Severe Plaque Psoriasis Medications Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Sandoz Main Business
Table 87. Sandoz Latest Developments
Table 88. Amgen Basic Information, Moderate to Severe Plaque Psoriasis Medications Manufacturing Base, Sales Area and Its Competitors
Table 89. Amgen Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
Table 90. Amgen Moderate to Severe Plaque Psoriasis Medications Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Amgen Main Business
Table 92. Amgen Latest Developments
Table 93. Eli Lilly Basic Information, Moderate to Severe Plaque Psoriasis Medications Manufacturing Base, Sales Area and Its Competitors
Table 94. Eli Lilly Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
Table 95. Eli Lilly Moderate to Severe Plaque Psoriasis Medications Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Eli Lilly Main Business
Table 97. Eli Lilly Latest Developments
Table 98. Novartis Basic Information, Moderate to Severe Plaque Psoriasis Medications Manufacturing Base, Sales Area and Its Competitors
Table 99. Novartis Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
Table 100. Novartis Moderate to Severe Plaque Psoriasis Medications Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Novartis Main Business
Table 102. Novartis Latest Developments
Table 103. Sun Pharmaceutical Industries Basic Information, Moderate to Severe Plaque Psoriasis Medications Manufacturing Base, Sales Area and Its Competitors
Table 104. Sun Pharmaceutical Industries Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
Table 105. Sun Pharmaceutical Industries Moderate to Severe Plaque Psoriasis Medications Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Sun Pharmaceutical Industries Main Business
Table 107. Sun Pharmaceutical Industries Latest Developments
Table 108. UCB, Inc Basic Information, Moderate to Severe Plaque Psoriasis Medications Manufacturing Base, Sales Area and Its Competitors
Table 109. UCB, Inc Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
Table 110. UCB, Inc Moderate to Severe Plaque Psoriasis Medications Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. UCB, Inc Main Business
Table 112. UCB, Inc Latest Developments
Table 113. Dermavant Sciences Basic Information, Moderate to Severe Plaque Psoriasis Medications Manufacturing Base, Sales Area and Its Competitors
Table 114. Dermavant Sciences Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
Table 115. Dermavant Sciences Moderate to Severe Plaque Psoriasis Medications Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Dermavant Sciences Main Business
Table 117. Dermavant Sciences Latest Developments
Table 118. GSK Basic Information, Moderate to Severe Plaque Psoriasis Medications Manufacturing Base, Sales Area and Its Competitors
Table 119. GSK Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
Table 120. GSK Moderate to Severe Plaque Psoriasis Medications Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. GSK Main Business
Table 122. GSK Latest Developments
Table 1. Moderate to Severe Plaque Psoriasis Medications Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Moderate to Severe Plaque Psoriasis Medications Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Injection
Table 4. Major Players of Oral
Table 5. Major Players of Topical Cream
Table 6. Global Moderate to Severe Plaque Psoriasis Medications Sales by Type (2021-2026) & (K Units)
Table 7. Global Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Type (2021-2026)
Table 8. Global Moderate to Severe Plaque Psoriasis Medications Revenue by Type (2021-2026) & ($ million)
Table 9. Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Type (2021-2026)
Table 10. Global Moderate to Severe Plaque Psoriasis Medications Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Global Moderate to Severe Plaque Psoriasis Medications Sale by Application (2021-2026) & (K Units)
Table 12. Global Moderate to Severe Plaque Psoriasis Medications Sale Market Share by Application (2021-2026)
Table 13. Global Moderate to Severe Plaque Psoriasis Medications Revenue by Application (2021-2026) & ($ million)
Table 14. Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Application (2021-2026)
Table 15. Global Moderate to Severe Plaque Psoriasis Medications Sale Price by Application (2021-2026) & (US$/Unit)
Table 16. Global Moderate to Severe Plaque Psoriasis Medications Sales by Company (2021-2026) & (K Units)
Table 17. Global Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Company (2021-2026)
Table 18. Global Moderate to Severe Plaque Psoriasis Medications Revenue by Company (2021-2026) & ($ millions)
Table 19. Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Company (2021-2026)
Table 20. Global Moderate to Severe Plaque Psoriasis Medications Sale Price by Company (2021-2026) & (US$/Unit)
Table 21. Key Manufacturers Moderate to Severe Plaque Psoriasis Medications Producing Area Distribution and Sales Area
Table 22. Players Moderate to Severe Plaque Psoriasis Medications Products Offered
Table 23. Moderate to Severe Plaque Psoriasis Medications Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Moderate to Severe Plaque Psoriasis Medications Sales by Geographic Region (2021-2026) & (K Units)
Table 27. Global Moderate to Severe Plaque Psoriasis Medications Sales Market Share Geographic Region (2021-2026)
Table 28. Global Moderate to Severe Plaque Psoriasis Medications Revenue by Geographic Region (2021-2026) & ($ millions)
Table 29. Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Geographic Region (2021-2026)
Table 30. Global Moderate to Severe Plaque Psoriasis Medications Sales by Country/Region (2021-2026) & (K Units)
Table 31. Global Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Country/Region (2021-2026)
Table 32. Global Moderate to Severe Plaque Psoriasis Medications Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas Moderate to Severe Plaque Psoriasis Medications Sales by Country (2021-2026) & (K Units)
Table 35. Americas Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Country (2021-2026)
Table 36. Americas Moderate to Severe Plaque Psoriasis Medications Revenue by Country (2021-2026) & ($ millions)
Table 37. Americas Moderate to Severe Plaque Psoriasis Medications Sales by Type (2021-2026) & (K Units)
Table 38. Americas Moderate to Severe Plaque Psoriasis Medications Sales by Application (2021-2026) & (K Units)
Table 39. APAC Moderate to Severe Plaque Psoriasis Medications Sales by Region (2021-2026) & (K Units)
Table 40. APAC Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Region (2021-2026)
Table 41. APAC Moderate to Severe Plaque Psoriasis Medications Revenue by Region (2021-2026) & ($ millions)
Table 42. APAC Moderate to Severe Plaque Psoriasis Medications Sales by Type (2021-2026) & (K Units)
Table 43. APAC Moderate to Severe Plaque Psoriasis Medications Sales by Application (2021-2026) & (K Units)
Table 44. Europe Moderate to Severe Plaque Psoriasis Medications Sales by Country (2021-2026) & (K Units)
Table 45. Europe Moderate to Severe Plaque Psoriasis Medications Revenue by Country (2021-2026) & ($ millions)
Table 46. Europe Moderate to Severe Plaque Psoriasis Medications Sales by Type (2021-2026) & (K Units)
Table 47. Europe Moderate to Severe Plaque Psoriasis Medications Sales by Application (2021-2026) & (K Units)
Table 48. Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Sales by Country (2021-2026) & (K Units)
Table 49. Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Country (2021-2026)
Table 50. Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Sales by Type (2021-2026) & (K Units)
Table 51. Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Sales by Application (2021-2026) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Moderate to Severe Plaque Psoriasis Medications
Table 53. Key Market Challenges & Risks of Moderate to Severe Plaque Psoriasis Medications
Table 54. Key Industry Trends of Moderate to Severe Plaque Psoriasis Medications
Table 55. Moderate to Severe Plaque Psoriasis Medications Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Moderate to Severe Plaque Psoriasis Medications Distributors List
Table 58. Moderate to Severe Plaque Psoriasis Medications Customer List
Table 59. Global Moderate to Severe Plaque Psoriasis Medications Sales Forecast by Region (2027-2032) & (K Units)
Table 60. Global Moderate to Severe Plaque Psoriasis Medications Revenue Forecast by Region (2027-2032) & ($ millions)
Table 61. Americas Moderate to Severe Plaque Psoriasis Medications Sales Forecast by Country (2027-2032) & (K Units)
Table 62. Americas Moderate to Severe Plaque Psoriasis Medications Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 63. APAC Moderate to Severe Plaque Psoriasis Medications Sales Forecast by Region (2027-2032) & (K Units)
Table 64. APAC Moderate to Severe Plaque Psoriasis Medications Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Europe Moderate to Severe Plaque Psoriasis Medications Sales Forecast by Country (2027-2032) & (K Units)
Table 66. Europe Moderate to Severe Plaque Psoriasis Medications Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Global Moderate to Severe Plaque Psoriasis Medications Sales Forecast by Type (2027-2032) & (K Units)
Table 70. Global Moderate to Severe Plaque Psoriasis Medications Revenue Forecast by Type (2027-2032) & ($ millions)
Table 71. Global Moderate to Severe Plaque Psoriasis Medications Sales Forecast by Application (2027-2032) & (K Units)
Table 72. Global Moderate to Severe Plaque Psoriasis Medications Revenue Forecast by Application (2027-2032) & ($ millions)
Table 73. Janssen Biotech Basic Information, Moderate to Severe Plaque Psoriasis Medications Manufacturing Base, Sales Area and Its Competitors
Table 74. Janssen Biotech Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
Table 75. Janssen Biotech Moderate to Severe Plaque Psoriasis Medications Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Janssen Biotech Main Business
Table 77. Janssen Biotech Latest Developments
Table 78. Abbvie Basic Information, Moderate to Severe Plaque Psoriasis Medications Manufacturing Base, Sales Area and Its Competitors
Table 79. Abbvie Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
Table 80. Abbvie Moderate to Severe Plaque Psoriasis Medications Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Abbvie Main Business
Table 82. Abbvie Latest Developments
Table 83. Sandoz Basic Information, Moderate to Severe Plaque Psoriasis Medications Manufacturing Base, Sales Area and Its Competitors
Table 84. Sandoz Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
Table 85. Sandoz Moderate to Severe Plaque Psoriasis Medications Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Sandoz Main Business
Table 87. Sandoz Latest Developments
Table 88. Amgen Basic Information, Moderate to Severe Plaque Psoriasis Medications Manufacturing Base, Sales Area and Its Competitors
Table 89. Amgen Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
Table 90. Amgen Moderate to Severe Plaque Psoriasis Medications Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Amgen Main Business
Table 92. Amgen Latest Developments
Table 93. Eli Lilly Basic Information, Moderate to Severe Plaque Psoriasis Medications Manufacturing Base, Sales Area and Its Competitors
Table 94. Eli Lilly Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
Table 95. Eli Lilly Moderate to Severe Plaque Psoriasis Medications Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Eli Lilly Main Business
Table 97. Eli Lilly Latest Developments
Table 98. Novartis Basic Information, Moderate to Severe Plaque Psoriasis Medications Manufacturing Base, Sales Area and Its Competitors
Table 99. Novartis Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
Table 100. Novartis Moderate to Severe Plaque Psoriasis Medications Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Novartis Main Business
Table 102. Novartis Latest Developments
Table 103. Sun Pharmaceutical Industries Basic Information, Moderate to Severe Plaque Psoriasis Medications Manufacturing Base, Sales Area and Its Competitors
Table 104. Sun Pharmaceutical Industries Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
Table 105. Sun Pharmaceutical Industries Moderate to Severe Plaque Psoriasis Medications Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Sun Pharmaceutical Industries Main Business
Table 107. Sun Pharmaceutical Industries Latest Developments
Table 108. UCB, Inc Basic Information, Moderate to Severe Plaque Psoriasis Medications Manufacturing Base, Sales Area and Its Competitors
Table 109. UCB, Inc Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
Table 110. UCB, Inc Moderate to Severe Plaque Psoriasis Medications Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. UCB, Inc Main Business
Table 112. UCB, Inc Latest Developments
Table 113. Dermavant Sciences Basic Information, Moderate to Severe Plaque Psoriasis Medications Manufacturing Base, Sales Area and Its Competitors
Table 114. Dermavant Sciences Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
Table 115. Dermavant Sciences Moderate to Severe Plaque Psoriasis Medications Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Dermavant Sciences Main Business
Table 117. Dermavant Sciences Latest Developments
Table 118. GSK Basic Information, Moderate to Severe Plaque Psoriasis Medications Manufacturing Base, Sales Area and Its Competitors
Table 119. GSK Moderate to Severe Plaque Psoriasis Medications Product Portfolios and Specifications
Table 120. GSK Moderate to Severe Plaque Psoriasis Medications Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. GSK Main Business
Table 122. GSK Latest Developments
LIST OF FIGURES
Figure 1. Picture of Moderate to Severe Plaque Psoriasis Medications
Figure 2. Moderate to Severe Plaque Psoriasis Medications Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Moderate to Severe Plaque Psoriasis Medications Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Moderate to Severe Plaque Psoriasis Medications Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Moderate to Severe Plaque Psoriasis Medications Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Country/Region (2025)
Figure 10. Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Injection
Figure 12. Product Picture of Oral
Figure 13. Product Picture of Topical Cream
Figure 14. Global Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Type in 2026
Figure 15. Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Type (2021-2026)
Figure 16. Moderate to Severe Plaque Psoriasis Medications Consumed in Hospital Clinic
Figure 17. Global Moderate to Severe Plaque Psoriasis Medications Market: Hospital Clinic (2021-2026) & (K Units)
Figure 18. Moderate to Severe Plaque Psoriasis Medications Consumed in Pharmacy
Figure 19. Global Moderate to Severe Plaque Psoriasis Medications Market: Pharmacy (2021-2026) & (K Units)
Figure 20. Moderate to Severe Plaque Psoriasis Medications Consumed in Online Shopping Mall
Figure 21. Global Moderate to Severe Plaque Psoriasis Medications Market: Online Shopping Mall (2021-2026) & (K Units)
Figure 22. Global Moderate to Severe Plaque Psoriasis Medications Sale Market Share by Application (2025)
Figure 23. Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Application in 2026
Figure 24. Moderate to Severe Plaque Psoriasis Medications Sales by Company in 2026 (K Units)
Figure 25. Global Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Company in 2026
Figure 26. Moderate to Severe Plaque Psoriasis Medications Revenue by Company in 2026 ($ millions)
Figure 27. Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Company in 2026
Figure 28. Global Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Geographic Region (2021-2026)
Figure 29. Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Geographic Region in 2026
Figure 30. Americas Moderate to Severe Plaque Psoriasis Medications Sales 2021-2026 (K Units)
Figure 31. Americas Moderate to Severe Plaque Psoriasis Medications Revenue 2021-2026 ($ millions)
Figure 32. APAC Moderate to Severe Plaque Psoriasis Medications Sales 2021-2026 (K Units)
Figure 33. APAC Moderate to Severe Plaque Psoriasis Medications Revenue 2021-2026 ($ millions)
Figure 34. Europe Moderate to Severe Plaque Psoriasis Medications Sales 2021-2026 (K Units)
Figure 35. Europe Moderate to Severe Plaque Psoriasis Medications Revenue 2021-2026 ($ millions)
Figure 36. Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Sales 2021-2026 (K Units)
Figure 37. Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Revenue 2021-2026 ($ millions)
Figure 38. Americas Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Country in 2026
Figure 39. Americas Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Country (2021-2026)
Figure 40. Americas Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Type (2021-2026)
Figure 41. Americas Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Application (2021-2026)
Figure 42. United States Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 43. Canada Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 44. Mexico Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 45. Brazil Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 46. APAC Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Region in 2026
Figure 47. APAC Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Region (2021-2026)
Figure 48. APAC Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Type (2021-2026)
Figure 49. APAC Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Application (2021-2026)
Figure 50. China Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 51. Japan Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 52. South Korea Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 53. Southeast Asia Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 54. India Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 55. Australia Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 56. China Taiwan Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 57. Europe Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Country in 2026
Figure 58. Europe Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Country (2021-2026)
Figure 59. Europe Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Type (2021-2026)
Figure 60. Europe Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Application (2021-2026)
Figure 61. Germany Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 62. France Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 63. UK Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 64. Italy Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 65. Russia Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 66. Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Country (2021-2026)
Figure 67. Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Type (2021-2026)
Figure 68. Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Application (2021-2026)
Figure 69. Egypt Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 70. South Africa Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 71. Israel Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 72. Turkey Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 73. GCC Countries Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Moderate to Severe Plaque Psoriasis Medications in 2026
Figure 75. Manufacturing Process Analysis of Moderate to Severe Plaque Psoriasis Medications
Figure 76. Industry Chain Structure of Moderate to Severe Plaque Psoriasis Medications
Figure 77. Channels of Distribution
Figure 78. Global Moderate to Severe Plaque Psoriasis Medications Sales Market Forecast by Region (2027-2032)
Figure 79. Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share Forecast by Region (2027-2032)
Figure 80. Global Moderate to Severe Plaque Psoriasis Medications Sales Market Share Forecast by Type (2027-2032)
Figure 81. Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share Forecast by Type (2027-2032)
Figure 82. Global Moderate to Severe Plaque Psoriasis Medications Sales Market Share Forecast by Application (2027-2032)
Figure 83. Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Moderate to Severe Plaque Psoriasis Medications
Figure 2. Moderate to Severe Plaque Psoriasis Medications Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Moderate to Severe Plaque Psoriasis Medications Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Moderate to Severe Plaque Psoriasis Medications Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Moderate to Severe Plaque Psoriasis Medications Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Country/Region (2025)
Figure 10. Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Injection
Figure 12. Product Picture of Oral
Figure 13. Product Picture of Topical Cream
Figure 14. Global Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Type in 2026
Figure 15. Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Type (2021-2026)
Figure 16. Moderate to Severe Plaque Psoriasis Medications Consumed in Hospital Clinic
Figure 17. Global Moderate to Severe Plaque Psoriasis Medications Market: Hospital Clinic (2021-2026) & (K Units)
Figure 18. Moderate to Severe Plaque Psoriasis Medications Consumed in Pharmacy
Figure 19. Global Moderate to Severe Plaque Psoriasis Medications Market: Pharmacy (2021-2026) & (K Units)
Figure 20. Moderate to Severe Plaque Psoriasis Medications Consumed in Online Shopping Mall
Figure 21. Global Moderate to Severe Plaque Psoriasis Medications Market: Online Shopping Mall (2021-2026) & (K Units)
Figure 22. Global Moderate to Severe Plaque Psoriasis Medications Sale Market Share by Application (2025)
Figure 23. Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Application in 2026
Figure 24. Moderate to Severe Plaque Psoriasis Medications Sales by Company in 2026 (K Units)
Figure 25. Global Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Company in 2026
Figure 26. Moderate to Severe Plaque Psoriasis Medications Revenue by Company in 2026 ($ millions)
Figure 27. Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Company in 2026
Figure 28. Global Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Geographic Region (2021-2026)
Figure 29. Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Geographic Region in 2026
Figure 30. Americas Moderate to Severe Plaque Psoriasis Medications Sales 2021-2026 (K Units)
Figure 31. Americas Moderate to Severe Plaque Psoriasis Medications Revenue 2021-2026 ($ millions)
Figure 32. APAC Moderate to Severe Plaque Psoriasis Medications Sales 2021-2026 (K Units)
Figure 33. APAC Moderate to Severe Plaque Psoriasis Medications Revenue 2021-2026 ($ millions)
Figure 34. Europe Moderate to Severe Plaque Psoriasis Medications Sales 2021-2026 (K Units)
Figure 35. Europe Moderate to Severe Plaque Psoriasis Medications Revenue 2021-2026 ($ millions)
Figure 36. Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Sales 2021-2026 (K Units)
Figure 37. Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Revenue 2021-2026 ($ millions)
Figure 38. Americas Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Country in 2026
Figure 39. Americas Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Country (2021-2026)
Figure 40. Americas Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Type (2021-2026)
Figure 41. Americas Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Application (2021-2026)
Figure 42. United States Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 43. Canada Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 44. Mexico Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 45. Brazil Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 46. APAC Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Region in 2026
Figure 47. APAC Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Region (2021-2026)
Figure 48. APAC Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Type (2021-2026)
Figure 49. APAC Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Application (2021-2026)
Figure 50. China Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 51. Japan Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 52. South Korea Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 53. Southeast Asia Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 54. India Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 55. Australia Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 56. China Taiwan Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 57. Europe Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Country in 2026
Figure 58. Europe Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Country (2021-2026)
Figure 59. Europe Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Type (2021-2026)
Figure 60. Europe Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Application (2021-2026)
Figure 61. Germany Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 62. France Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 63. UK Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 64. Italy Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 65. Russia Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 66. Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Country (2021-2026)
Figure 67. Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Type (2021-2026)
Figure 68. Middle East & Africa Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Application (2021-2026)
Figure 69. Egypt Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 70. South Africa Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 71. Israel Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 72. Turkey Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 73. GCC Countries Moderate to Severe Plaque Psoriasis Medications Revenue Growth 2021-2026 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Moderate to Severe Plaque Psoriasis Medications in 2026
Figure 75. Manufacturing Process Analysis of Moderate to Severe Plaque Psoriasis Medications
Figure 76. Industry Chain Structure of Moderate to Severe Plaque Psoriasis Medications
Figure 77. Channels of Distribution
Figure 78. Global Moderate to Severe Plaque Psoriasis Medications Sales Market Forecast by Region (2027-2032)
Figure 79. Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share Forecast by Region (2027-2032)
Figure 80. Global Moderate to Severe Plaque Psoriasis Medications Sales Market Share Forecast by Type (2027-2032)
Figure 81. Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share Forecast by Type (2027-2032)
Figure 82. Global Moderate to Severe Plaque Psoriasis Medications Sales Market Share Forecast by Application (2027-2032)
Figure 83. Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share Forecast by Application (2027-2032)
